Incretin Therapies in Obesity-related HFpEF

NCT07554638 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether incretin-based therapies can help reduce fluid buildup in people with obesity-related heart failure that preserves normal ejection fraction.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 50 people Planned (estimated).

Who can join Ages 40+ · all sexes

Timeline Started 2026-06 · est. completion 2030-04

What this study is testing ClinicalTrials.gov NCT07554638 ↗

Description as written by the study sponsor.

The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. In conjunction with state-of-the-art body composition analysis and measures of adipokines, this will establish an important mechanism of clinical benefit and inform disease pathophysiology. To accomplish this, this study will perform a 15-month prospective cohort study in 50 patients with obesity and HFpEF who clinically qualify for treatment with tirzepatide. The investigators will serially measure plasma volume and body composition with quantitative magnetic resonance to determine changes over time with tirzepatide treatment.

Treatments tested

Tirzepatide also known as Mounjaro Drug

Glucagon-like 1 receptor agonist/glucose-dependent insulinotropic polypeptide receptor agonist

Main thing measured	Plasma volume
Sponsor	Columbia University
Conditions studied	Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07554638 ↗